

RealRate

PHARMACEUTICAL 2020

Epizyme Inc. Rank 49 of 358









RealRate

PHARMACEUTICAL 2020

Epizyme Inc. Rank 49 of 358



The relative strengths and weaknesses of Epizyme Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Epizyme Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 86% points. The greatest weakness of Epizyme Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 218%, being 182% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	399,177
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	34,386
Liabilities, Non-Current	0
Other Assets	23,193
Other Compr. Net Income	73
Other Expenses	58
Other Liabilities	0
Other Net Income	6,905
Other Revenues	23,800
Property and Equipment	2,219
Research and Development	132,639
Selling, General and Administrative Expense	68,303

Output Variable	Value in 1000 USD
Assets	424,589
Liabilities	34,386
Expenses	201,000
Revenues	23,800
Stockholders Equity	390,203
Net Income	-170,295
Comprehensive Net Income	-170,258
Economic Capital Ratio	218%

